Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients Compared to Healthy Individuals: A Systematic Review and Meta-Analysis - Scorecard - MDSpire
Advertisement
Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients Compared to Healthy Individuals: A Systematic Review and Meta-Analysis
Clinical Scorecard: Prevalence and Contributing Factors of Hypothyroidism in Hematological Malignancy Patients Compared to Healthy Individuals: A Systematic Review and Meta-Analysis
At a Glance
Category
Detail
Condition
Key Mechanisms
Endocrine complications due to treatments like chemotherapy and radiotherapy, specifically leading to hypothyroidism.
Target Population
Care Setting
Key Highlights
Higher incidence of hypothyroidism in HM patients compared to healthy individuals, particularly in specific malignancies like leukemia and lymphoma.
Risk factors include type of malignancy, gender, and treatment received, with specific mention of chemotherapy and radiotherapy.
Guideline-Based Recommendations
Diagnosis
Management
Implement regular screening for hypothyroidism in patients undergoing treatment for HMs.
Consider treatment options for hypothyroidism when diagnosed.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Chemotherapy regimens such as TBI and specific agents can lead to increased risk of hypothyroidism.
Clinical Best Practices
Utilize a multidisciplinary approach for managing endocrine complications in HM patients, including endocrinologists.
Educate patients about the risk of hypothyroidism and the importance of monitoring, providing resources for self-management.
